Superhuman Inc. v. ThermoLife International LLC: Supplement Patent Dispute Ends in 36 Days
Superhuman Inc. filed a patent infringement action against ThermoLife International LLC in the Southern District of Florida, asserting US8455531B2 in connection with Superhuman Supplements. The case closed just 36 days after filing via voluntary dismissal without prejudice — one of the fastest closures seen in district court patent litigation.
A 36-Day Patent Suit: Early Exit Leaves the Door Open
On September 30, 2024, Superhuman Inc. filed a patent infringement action against ThermoLife International LLC in the U.S. District Court for the Southern District of Florida (Case No. 1:24-cv-23765). The suit asserted US8455531B2 — a patent associated with dietary and sports supplement formulations — in connection with Superhuman Supplements products. ThermoLife International LLC, a well-known player in the sports nutrition and supplement licensing space, was named as the sole defendant.
The case closed on November 5, 2024 — just 36 days after filing — when Superhuman Inc. filed a notice of voluntary dismissal without prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). This procedural mechanism allows a plaintiff to unilaterally dismiss before a defendant has served an answer or motion for summary judgment. Crucially, a dismissal without prejudice means the claims are not extinguished: Superhuman Inc. retains the legal right to refile the same infringement allegations at a future date.
The 36-day duration is notably short, suggesting the dismissal occurred before any substantive litigation activity — no answer, no scheduling order, and almost certainly no discovery. The public record does not disclose what drove the decision to dismiss, but early voluntary dismissals of this kind can reflect private settlement discussions, a strategic pause to reassess claim scope, or an intent to refile in a different venue or forum. The absence of a costs or fees ruling is consistent with the pre-answer timing of the dismissal.
Filing to Voluntary dismissal in 36 days
36 days — well below the median district court patent case duration of 2+ years
Voluntarily dismissed: what Rule 41 without prejudice means for both sides
Rule 41(a)(1)(A)(i): plaintiff’s unilateral exit right
Federal Rule of Civil Procedure 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order — and without prejudice — at any time before the defendant serves an answer or a motion for summary judgment. No judicial approval is required. The dismissal is self-executing upon filing of the notice. This is among the most procedurally straightforward exits available in federal civil litigation.
Pre-answer voluntary dismissalWithout prejudice: the distinction that matters most
A dismissal ‘with prejudice’ extinguishes the claims permanently — the plaintiff cannot refile. A dismissal ‘without prejudice’ preserves the right to bring the same claims again. Here, the notice expressly states ‘without prejudice,’ meaning Superhuman Inc.’s infringement claims under US8455531B2 survive the dismissal. The public record does not disclose whether a settlement was reached or whether refiling is anticipated.
Right to refile preservedSuperhuman Inc.: strategic flexibility retained
By dismissing without prejudice at the pre-answer stage, Superhuman Inc. avoids any adverse merits ruling while keeping its patent enforcement options open. The company can refile in the same court, choose an alternative venue, or use the filing as leverage in licensing discussions. There is no judgment on the record that could be cited against it in future proceedings involving US8455531B2.
No merits concession madeThermoLife: threat not extinguished, costs unawarded
ThermoLife International LLC secured an exit from this specific action without incurring a merits loss, but the without-prejudice dismissal means the infringement risk under US8455531B2 is not permanently resolved. ThermoLife cannot use this dismissal to establish claim preclusion in a future suit. No award of attorney fees or costs was recorded, which is typical where dismissal precedes any substantive response from the defendant.
Ongoing exposure not extinguishedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Superhuman Inc. | Company | Sports supplement brand — holder of US8455531B2 covering supplement formulationsSearch in Eureka ↗ |
| Defendant | ThermoLife International LLC | Company | ThermoLife International LLC — sports nutrition ingredient licensor and supplement companySearch in Eureka ↗ |
| Plaintiff counsel | A. Colin Wexler | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff counsel | Paul J. Sauerteig | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Guerra | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert D. Leighton | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff law firm | Goldberg Kohn Ltd. | Law Firm | Representing Superhuman Inc.Search in Eureka ↗ |
| Plaintiff law firm | The Brickell Ip Group, PLLC | Law Firm | Representing Superhuman Inc.Search in Eureka ↗ |
| Defendant counsel | Derek Dahlgren | Attorney | Counsel for ThermoLife International LLCSearch in Eureka ↗ |
| Defendant counsel | Jorge Tadeo Espinosa | Attorney | Counsel for ThermoLife International LLCSearch in Eureka ↗ |
| Defendant counsel | Timothy Devlin | Attorney | Counsel for ThermoLife International LLCSearch in Eureka ↗ |
| Defendant law firm | Devlin Law Firm LLC | Law Firm | Representing ThermoLife International LLCSearch in Eureka ↗ |
| Defendant law firm | GrayRobinson PA | Law Firm | Representing ThermoLife International LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Florida Southern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and expressly states ‘without prejudice,’ meaning no merits adjudication occurred. The court made no findings on infringement, validity, or claim construction. For Superhuman Inc., the phrasing preserves all enforcement rights under US8455531B2. For ThermoLife, there is no res judicata or issue preclusion benefit from this record. The absence of any fee or costs motion filed by ThermoLife before dismissal is consistent with the pre-answer timing.
US8455531B2 — dietary and sports supplement formulation patent
US8455531B2 is a U.S. utility patent asserted in connection with Superhuman Supplements products. The application number US13/038537 indicates a filing in the standard utility patent track. The patent sits within the dietary supplement and sports nutrition formulation space — a sector characterised by active IP enforcement and a high volume of composition-of-matter and method-of-use claims. The granted B2 designation confirms the patent issued after examination with at least one amendment cycle.
In the sports nutrition sector, formulation patents carry significant commercial leverage: a single patent covering an ingredient combination or dosage methodology can affect an entire product line. ThermoLife International is known for licensing patented ingredients to supplement brands, which makes it a strategically distinctive defendant — both a potential infringer and a company with its own extensive IP portfolio. Competitors and formulators working in overlapping categories should assess their exposure to US8455531B2 claims independently of the outcome of this case.
Should you run an FTO analysis against US8455531B2?
Any company developing, manufacturing, or distributing dietary supplements or sports nutrition products that could overlap with the formulation or compositional claims of US8455531B2 should assess their freedom to operate. This is particularly relevant for brands using ThermoLife-licensed ingredients or formulations, private-label supplement manufacturers, and any company that competes directly in the Superhuman Supplements product category. The without-prejudice dismissal means Superhuman Inc. can refile — making proactive FTO analysis commercially prudent now.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US8455531B2 against your current formulations and flag overlapping granted patents, published applications, and related prior art. Eureka can also surface the full prosecution history and any related continuations or divisionals that may extend the effective patent family. For product teams in the supplement space, this is faster and more cost-effective than commissioning a full written opinion before an initial risk screen.
Run a freedom-to-operate analysis on US8455531B2 to assess your product’s exposure
Run FTO in Eureka →Similar supplement formulation patent cases in U.S. district courts
Explore comparable patent infringement actions involving dietary supplement and sports nutrition formulation patents filed in Florida and other U.S. district courts.
What this case signals for the sports supplement IP landscape
A 36-day case closure rarely signals resolution — in supplement patent disputes, it often signals the beginning of a longer strategic play.
Early voluntary dismissals are not clean exits — monitor for refiling
When a patent plaintiff dismisses without prejudice after just 36 days, the risk does not disappear. Competitors and defendants in the supplement sector should monitor for re-filed actions, continuation patents, or licensing demand letters referencing the same underlying IP. The without-prejudice posture explicitly preserves the plaintiff’s enforcement hand.
US8455531B2 remains an active enforcement asset for Superhuman Inc.
No court has ruled on the validity or infringement scope of US8455531B2. The patent survived this case intact and without any adverse ruling. Any company operating in the sports nutrition or dietary supplement formulation space that overlaps with the claims of this patent should treat it as an unresolved risk — particularly if ThermoLife-derived ingredients or formulation methods are in use.
Superhuman v ThermoLife — key questions answered
Superhuman Inc. filed a patent infringement action against ThermoLife International LLC in the Southern District of Florida on September 30, 2024, asserting US8455531B2 in connection with Superhuman Supplements. The case was voluntarily dismissed without prejudice by Superhuman Inc. on November 5, 2024 — 36 days after filing — before ThermoLife filed any answer or dispositive motion.
A dismissal without prejudice under Rule 41(a)(1)(A)(i) means the infringement claims are not extinguished. Superhuman Inc. retains the legal right to refile the same claims against ThermoLife International LLC or other parties in the future. No court made any finding on infringement, validity, or claim scope of US8455531B2.
US8455531B2 is a U.S. granted utility patent (application number US13/038537) asserted by Superhuman Inc. in connection with its Superhuman Supplements products. It relates to dietary and sports supplement formulation technology. The B2 designation indicates the patent issued following examination with amendments. The full claim scope is set out in the patent’s prosecution history available via the USPTO.
The public record does not disclose the reason for the early dismissal. Common drivers for pre-answer voluntary dismissals include confidential settlement or licensing discussions, a strategic decision to refile in a different venue, a reassessment of claim scope following initial case preparation, or resolution of the underlying commercial dispute. The without-prejudice election suggests Superhuman Inc. did not intend a permanent abandonment of its enforcement position.
No. Because the dismissal was without prejudice and no merits adjudication occurred, ThermoLife cannot invoke res judicata or issue preclusion against Superhuman Inc. in any future action based on US8455531B2. The case closed before ThermoLife filed an answer, so no substantive legal positions were litigated or decided. ThermoLife’s patent infringement exposure under this patent remains legally unresolved.
PatSnap Eureka searches patents and litigation data to answer instantly.